RMC-0708: First-in-Class Mutant-Selective RAS(ON) Inhibitor for KRASQ61H Cancers
Time: 4:45 pm
day: Conference Day One
- KRASQ61H mutant cancers represent an unmet medical need and include common solid tumor histotypes such NSCLC, PDAC, and CRC.
- RMC-0708 is a first-in-class, orally bioavailable, mutant-selective, and non-covalent inhibitor of KRASQ61H(ON).
- RMC-0708 potently suppresses p-ERK and proliferation in KRASQ61H mutant cancer cells while displaying selectivity against wildtype KRAS.
- RMC-0708 demonstrates anti-tumor activity in various preclinical models of human KRASQ61H tumors.